|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Mar 10, 2026
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q3 FY2023
As of Aug 31, 2023
|
Q2 FY2023
As of May 31, 2023
|
Q1 FY2023
As of Feb 28, 2023
|
Q4 FY2022
As of Nov 30, 2022
|
Q3 FY2022
As of Aug 31, 2022
|
Q2 FY2022
As of May 31, 2022
|
Q1 FY2022
As of Feb 28, 2022
|
Q4 FY2021
As of Nov 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Current assets | ||||||||||||||||||
| Certificate of deposit | ||||||||||||||||||
| Short-term investments | ||||||||||||||||||
| Cash | ||||||||||||||||||
| Restricted cash | ||||||||||||||||||
| Accounts receivable | ||||||||||||||||||
| Inventories | ||||||||||||||||||
| Other receivable | ||||||||||||||||||
| Advance to suppliers | ||||||||||||||||||
| Value added tax receivable, current | ||||||||||||||||||
| Total current assets | ||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||
| Value added tax receivable | ||||||||||||||||||
| Notes receivable | ||||||||||||||||||
| Total noncurrent assets | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||
| Current liabilities | ||||||||||||||||||
| Short-term bank loans | ||||||||||||||||||
| Convertible notes payable | ||||||||||||||||||
| Accounts payable | ||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||
| Deferred income | ||||||||||||||||||
| Deferred income, current | ||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||
| Convertible notes payable, net | ||||||||||||||||||
| Total current liabilities | ||||||||||||||||||
| Deferred income | ||||||||||||||||||
| Long-term payable | ||||||||||||||||||
| Noncurrent liabilities of discontinued operations | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Commitments and contingencies | ||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||
| Common stock, $0.001 par value; 65,000,000 shares authorized; 15,591,376 and 25,899,468 shares issued and outstanding, respectively | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Total ESG Inc. stockholders’ equity (deficit) | ||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||
| Total equity (deficit) | ||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||
Loading...
